Expert Radar
Dr. Philip Philip, MD, PhD, FRCP
Co-Director/Co-Leader, Henry Ford Health (Detroit, MI)
Doctor of Medicine
Dr. Philip A. Philip has over 29 years of experience in the field of Internal Medicine. He earned his MD from the University of Baghdad, College of Medicine, and his PhD in Clinical Pharmacology and Pharmacogenetics from the University of London. After completing his residency in Internal Medicine at Al-Taji Hospital and Baghdad Medical City, he went on to complete a fellowship in Medical Oncology at MD Anderson Cancer Center. Today this expert is board-certified in Medical Oncology. Formerly, he held roles as an Associate Professor of Medicine and Professor of Hematology/Oncology at Wayne State University School of Medicine. Currently, he serves as a Professor in the Departments of Oncology, Internal Medicine, and Pharmacology at Wayne State University School of Medicine, as the Medical Director of Research and Clinical Care Integration at Henry Ford Cancer Institute, and as the Endowed Dr. Kathryn Cramer Professor and Chair of Cancer Research at Karmanos Cancer Institute.
a********@*****.edu
(313) ***-****
Detroit, Michigan
Get a FREE Demo of Dr. Philip Philip, MD, PhD, FRCP's Radar Profile
Review this expert's litigation history, supporting legal docs, publications, professional background, and more.
Comprehensive data on expert witnesses: Access detailed litigation history and performance metrics.
Swift assessment: Quickly evaluate an expert's track record.
Informed decisions: Make better choices when selecting or challenging expert witnesses in any case.
DISCLAIMER: Expert Institute operates independently and objectively as an expert witness data provider. This listing does not reflect or imply any existing relationship between the expert and Expert Institute. We do not employ, endorse, or maintain any affiliation with the experts listed. Information shown is automatically generated from public sources and may not be current or complete. For verified, in-depth expert data, please contact us to initiate a formal request.
Expert Witness Activity
Plaintiff Cases
Defense Cases
Expert Challenges
5
Deposition Transcripts
Publications
426
Media & News
592
Social Media Mentions
Radar found 16 records
Case Name | Role | Filed Date |
|---|---|---|
Laurence Benison Individually, et al. v. Glen Cove Hospital, et al. | Examining Physician | 2023-08-07 |
Joel Handorff, et al. v. Village Center for Care, et al. | Examining Physician | 2020-09-24 |
Robert Stanislaro v. Mary Ann Hopkins M.D., et al. | Examining Physician | 2016-02-16 |
Radar monitors both national and state court systems to track litigation activity and access court documents.
View case details, documents, plaintiff and defense representation, defendants, judges, jurisdiction, and more.

Defense
Plaintiff
0
25
50
75
100
2000
0
2002
0
2004
0
2006
0
2008
0
2010
0

0
25
50
75
100
Institution | Degree Type |
|---|---|
— | Doctor of Medicine |
University of London | Doctor of Philosophy |
Radar found 10 records
Title | Employer |
|---|---|
Co-Director/Co-Leader | Henry Ford Health (Detroit, MI) |
Medical Director | Henry Ford Health (Detroit, MI) |
Director | Henry Ford Health (Detroit, MI) |
Endowed Dr. Kathryn Cramer Professor and Chair | Karmanos Cancer Institute (Detroi, MI) |
Medical Oncologist | Karmanos Cancer Institute (Detroi, MI) |
Senior Staff Physician | Henry Ford Cancer Institute (Detroit, MI) |
Medical Director | Henry Ford Cancer Institute (Detroit, MI) |
Professor (Tenured) | Wayne State University School of Medicine (Detroit, MI) |
Professor (Tenured) | Wayne State University School of Medicine (Detroit, MI) |
Professor | Wayne State University School of Medicine (Detroit, MI) |
Radar found 426 records
Title | Type |
|---|---|
Chemotherapy dose density is prognostic for overall survival in patients with resectable pancreas cancer: A landmark analysis of SWOG 1505 | Journal Article |
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers | Journal Article |
Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial | Journal Article |
Radar monitors a wide array of publication sources, including links to abstracts.
Review book chapters, journal articles, research papers, trade publications, technical reports, conference proceedings, and more.

Radar found 592 records
Title | Description |
|---|
Radar scours thousands of media and news sources across the internet 24/7.
Access interviews, webinars, TV appearances, blog posts, columns, whitepapers, PDFs, profressional profiles, and more.

Access detailed litigation history and performance metrics.
Access your Radar profile through Expert iQ, our secure, cloud-based platform that hosts AI-driven insights.
Delivered in 3–5 business days
Receive your profile swiftly, with Radar gathering intelligence from thousands of data points.
24/7 monitoring for 12 months
Stay informed with continuous monitoring and live alerts, ensuring your profile is always up-to-date.

